Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doravirine

FDA-approved product (tablet, oral), marketed as Pifeltro.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Doravirine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Doravirine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doravirine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

    NCT04892654 · start 2022-08-17

    Registered record
    Registry ID
    NCT04892654
    Conditions
    HIV-1-infection
    Interventions
    Doravirine; Dolutegravir; Triple cART regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-08-17
    Completion
    2027-11-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDoravirine; Dolutegravir; Triple cART regimen
    PhasePhase 3
    Registry statusRecruiting

  • Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

    NCT05502341 · start 2022-08-16

    Registered record
    Registry ID
    NCT05502341
    Conditions
    HIV-1-infection
    Interventions
    Bictegravir; Lenacapavir; BIC/LEN FDC; Stable Baseline Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2022-08-16
    Completion
    2028-07
    Enrolment
    689

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionBictegravir; Lenacapavir; BIC/LEN FDC; Stable Baseline Regimen
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Doravirine and Weight Gain in Antiretroviral Naive

    NCT05457530 · start 2022-08-01

    Registered record
    Registry ID
    NCT05457530
    Conditions
    Body Weight Changes; Human Immunodeficiency Virus; ART; Obesity; Minority Health; BMD; Metabolic Syndrome; Fasting
    Interventions
    DOR/3TC/TDF; DOR + FTC/TAF; BIC/FTC/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2022-08-01
    Completion
    2023-05-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBody Weight Changes; Human Immunodeficiency Virus; ART; Obesity +4 more
    InterventionDOR/3TC/TDF; DOR + FTC/TAF; BIC/FTC/TAF
    PhasePhase 3
    Registry statusWithdrawn

  • Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

    NCT04900974 · start 2022-06-09

    Registered record
    Registry ID
    NCT04900974
    Conditions
    HIV Infections; Pregnancy Related
    Interventions
    Doravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-09
    Completion
    2025-04-08
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Pregnancy Related
    InterventionDoravirine
    PhasePhase 1
    Registry statusCompleted

  • HIV A6 Genome In ART Unsuccessful Patients On DOR

    NCT05322083 · start 2022-05

    Registered record
    Registry ID
    NCT05322083
    Conditions
    Virus-HIV
    Interventions
    Doravirine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-05
    Completion
    2024-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVirus-HIV
    InterventionDoravirine
    PhaseNot recorded
    Registry statusUnknown

  • Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

    NCT04283656 · start 2022-01-04

    Registered record
    Registry ID
    NCT04283656
    Conditions
    Transgender Health; Gender Dysphoria; Transgender Women; Human Immunodeficiency Virus
    Interventions
    Doravirine/Lamivudine/Tenofovir; Spironolactone 100mg; Estradiol 2mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-01-04
    Completion
    2022-12-30
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransgender Health; Gender Dysphoria; Transgender Women; Human Immunodeficiency Virus
    InterventionDoravirine/Lamivudine/Tenofovir; Spironolactone 100mg; Estradiol 2mg; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge).

    NCT05202613 · start 2022-01-04

    Registered record
    Registry ID
    NCT05202613
    Conditions
    HIV
    Interventions
    Doravirine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-01-04
    Completion
    2022-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionDoravirine
    PhaseNot recorded
    Registry statusUnknown

  • Ambispective Cohort Study to Evaluate the Efficacy, Safety, and Tolerance of an Antiretroviral Regimen With Doravirine

    NCT05140603 · start 2021-12-01

    Registered record
    Registry ID
    NCT05140603
    Conditions
    Hiv
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-12-01
    Completion
    2023-10-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

    NCT04776252 · start 2021-09-15

    Registered record
    Registry ID
    NCT04776252
    Conditions
    HIV-1 Infection
    Interventions
    MK-8591A
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-09-15
    Completion
    2029-05-29
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionMK-8591A
    PhasePhase 3
    Registry statusActive not recruiting

  • Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

    NCT04518228 · start 2021-09-01

    Registered record
    Registry ID
    NCT04518228
    Conditions
    HIV; Tuberculosis
    Interventions
    Bictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG); Atazanavir/ritonavir (ATV/r); Darunavir/ritonavir (DRV/r); Lopinavir/ritonavir (LPV/r); Cobicistat; Ritonavir; First-Line TB Treatment; Second-Line TB Treatment; Doravirine (DOR)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-09-01
    Completion
    2025-07-10
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionBictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG) +8 more
    PhaseNot recorded
    Registry statusTerminated

  • Impact of V106I on Resistance to Doravirine

    NCT04894357 · start 2021-09-01

    Registered record
    Registry ID
    NCT04894357
    Conditions
    HIV-1-infection
    Interventions
    Phenotypic resistance measure
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-09-01
    Completion
    2022-05-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionPhenotypic resistance measure
    PhaseNot recorded
    Registry statusUnknown

  • Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

    NCT04636437 · start 2021-07-27

    Registered record
    Registry ID
    NCT04636437
    Conditions
    HIV Infections
    Interventions
    Doravirine 100 Mg; Integrase strand transfer inhibitors; Tenofovir alafenamide/emtricitabine; tenofovir disproxil fumarate/emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-07-27
    Completion
    2024-10-18
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDoravirine 100 Mg; Integrase strand transfer inhibitors; Tenofovir alafenamide/emtricitabine; tenofovir disproxil fumarate/emtricitabine
    PhasePhase 4
    Registry statusCompleted

  • Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

    NCT04689737 · start 2021-03-20

    Registered record
    Registry ID
    NCT04689737
    Conditions
    HIV-infected Participants With ESRD Undergoing Routine Hemodialysis
    Interventions
    Doravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-03-20
    Completion
    2021-06-14
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-infected Participants With ESRD Undergoing Routine Hemodialysis
    InterventionDoravirine
    PhasePhase 4
    Registry statusCompleted

  • ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance

    NCT04429152 · start 2021-02-09

    Registered record
    Registry ID
    NCT04429152
    Conditions
    HIV-1-infection
    Interventions
    Doravirine/Lamivudine/Tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-02-09
    Completion
    2023-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDoravirine/Lamivudine/Tenofovir
    PhasePhase 3
    Registry statusUnknown

  • Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

    NCT04375800 · start 2021-02-03

    Registered record
    Registry ID
    NCT04375800
    Conditions
    Human Immunodeficiency Virus (HIV) Infection
    Interventions
    Doravirine; 2 NRTIs; DOR/3TC/TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-02-03
    Completion
    2034-04-11
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV) Infection
    InterventionDoravirine; 2 NRTIs; DOR/3TC/TDF
    PhasePhase 2
    Registry statusRecruiting